The results of this study showed that the average age of the studied subjects was 32.4 years old, and the majority of them had diploma or a lower education and a normal social class. In this study and also in the other studies, in line with the results of our study, most people having MS were suffering from the “relapsing remitting” type and the most common primary symptom in them was vision impairment like our study. While Kaminska et al. (2011) identified fatigue as the first and most common symptom in MS patients (18). The results of our study also indicated that fatigue is the most common symptom that exacerbates during pregnancy, which is expected to increase fatigue during pregnancy in women with MS due to increased progesterone level.
The mean number of pregnancies in women with MS was 1.61 in the studied population. Ferraro’s study in 2017 indicated that MS disease was associated with an increase in the number of unmarried women compared to the general population (22% versus 13%) (19). A study in France also found that 30% of women with MS had no children, although in this study women were still at reproductive ages (20). Of the causes of childlessness in women suffering from MS are: reduced inclination to become a mother because of disability, fear of future disability, fear of genetic transmission of disease to child, the effect of pregnancy on severity of disease, the effect of illness on pregnancy, fear of stopping or starting treatment during pregnancy and not encouraging doctors to become pregnant. This issue can be largely controlled by proper awareness of affected women (21.22). In the present study, just one sample person had parity 4, and the rest of the women had 3 and less than 3 pregnancies and the results of this study which is consistent with other studies show that these women do not tend to have many children. Therefore, perhaps part of the low number of parity in these women can be attributed to postponement of pregnancy or the effect of drugs on infertility and MS-related sexual dysfunction (23). The results of the study showed that the reasons for the lack of willingness to have children in these people are depression, reduced social activity, disability because of illness, reduced maternity willingness and stress associated with coming down with a chronic disease (24). In the present study, 88.2% of the mothers have been housewives and this indicates a specific social inactivity in this group, which may be due to the reduction of childbearing. Studies also showed that women with a higher socioeconomic level tended to delay pregnancy (19). Considering that about 45% of the subjects had university education and most of the subjects of the study enjoyed a moderate economic level, it seems the results of our study also indicate that with increasing social and economic level, the tendency to delay and decrease in childbearing increases.
Although multiparous women are at a lower risk of MS attacks, the average childbearing frequency of mothers with MS in this study was 1.6. In this study, 33.0% of mothers had two pregnancies and only a small percentage of women had third and fourth pregnancy. Regarding this fact, it seems that by expressing the reduction of the risk of MS recurrence in multiparous women, the good role of pregnancy in MS can be considered. The risk of MS in multiparous women is lower than that of nulliparous women (25). Also, the results of the study by Ponsonby et al., showed that increasing parity rates plays a protective role against the progression of MS (demyelinating) disease (13). The results of the present study showed that MS did not affect the pregnancy status, including the number of abortions, ectopic pregnancy, and the number of alive and dead children. The study by Ferraro et al., also indicated that there is no difference in infertility, the use of Assisted Reproductive Technology (ART) fertility means, the time taken for pregnancy until becoming pregnant and abortion in the population of women with MS in relation to the general population, and even the time taking action for pregnancy until becoming pregnant in women with MS has been shorter than control group. The frequency of elective abortion in these women has been higher than general population (20% versus 12%). In our study, the average decision-making time for pregnancy until maternal pregnancy has been 8.4 months. Therefore, MS disease does not have a negative effect on maternal pregnancy. According to the definition, if people fail to become pregnant after one year of taking action for becoming pregnant, they belong to the definition of infertility, while the average time in our study was less than one year (about 8 months). In our study also 95.4% of the population did not have infertility history. Therefore, MS does not have a negative effect on Fertility.
The result of study showed motherhood does not seem to have negative effects on risk or course of MS, although the interpretations of all these studies need to factor a possible bias as women with severe course of the disease may tend to prevent pregnancies, and rather patients with severe form or late onset of the disease decide to become pregnant (26). Therefore, the use of fertility medications by 10.6% of the subjects does not mean MS-induced infertility in this population, but probably it has been because of the tendency and acceleration of fertility due to the control of the disease during that time period. Although the results of the study showed that the level of Anti-mullerian hormone, the number of follicles and the volume of ovaries (27) in patients with severe MS were less than those with mild type (28), but the subject that whether the reduction of ovarian storage reduces the menopause age or fertility rate in women with MS is unknown. Therefore, although there is a controversy over the fertility situation of women with MS (29), but the decline in ovarian function may affect the fertility potential. A recent epidemiological study has found no evidence of the effect of MS on fertility (30). The important note is that 22% of the population had unwanted pregnancy and pregnancy without any plans. Regarding the fact that 56.9% of people have chosen withdrawal contraceptive method and 1.8% have had no contraceptive method, this percentage of unwanted pregnancy was expected. Therefore, considering the importance of controlling the MS disease before pregnancy and the side effect of drugs on the fetus, more attention is needed and providing proper counseling about contraception in the health centers to these MS women is required. Despite the fact that studies show that hormonal methods are the most appropriate contraceptive method for this target group, just 7.3% of the subjects studied have had this method in the year before their pregnancy, which seems to be due to the low level of awareness of individuals and the inadequacy of receiving appropriate training from service providers. However, in a cohort study by Karp et al., 55% of the studied population used oral contraceptives (10). The results of the study showed that using oral contraceptive reduces the level of anti-mullerian hormone (31), and the use of this contraceptive method in women with MS has attracted lower attention than the general population (24–28% versus 50%).
The mean time interval of the last MS attack before pregnancy has been 21.36 months, and about 69.2% of the subjects had no attacks before the pregnancy. Therefore, given the favorable conditions of the disease before pregnancy, it seems that creating sensitivity to treatment by Neurologists have been appropriate before pregnancy.
The most commonly used drug in the year before and after pregnancy was Sinovex and Recigen. After making decision to become pregnant, 97.3% of the subjects under the supervision of the doctor had stopped the drug. Of those who stopped, 11.9% had recurrence of MS attacks. The subject indicates that at least amount of medication that the mothers have received and has been careful monitoring and supervision of doctors on MS patients before pregnancy. Therefore, the results suggest that the choice of drugs in a way to have low-risk for pregnancies, while at the same time that leads to minimal recurrence, has been considered by the experts. However, in a study, 40% of women before pregnancy have had to modify the dosage of drugs in the year before pregnancy (12).
During pregnancy, 93.7% of people did not take any medications, and 6.3% of the participants in the study (6 people) experienced relapses during pregnancy and used Glatiramer Acetate. Therefore, the results of the study showed that the participants in this study did not have a very active disease and were in a controlled phase of the disease, so only the first line drugs were received.
In the field of prenatal care, 56.2% of the participants in the study were taken care for more than 9 sessions, therefore, it seems that only half of the studied population have realized the importance of receiving adequate care and referral to service providing centers. But about 50% have not realized this importance, so that unfortunately, about 30% of people referred to service providing centers 4 times or less during their pregnancy, and perhaps the cases of recurrence of the disease are related to the population who referring to the service-providing centers (public health centers, neurologists, and obstetrics and gynecology clinics) has been below the standard. Therefore, it shows the importance of focusing on raising the awareness of mothers with MS.
Examining the effect of pregnancy on MS disease is very important, especially when it was initially thought that pregnancy would have a negative effect on the disease (32). The results of this study showed that fatigue, emotional and mood disorders, limb numbness, digestive and motor problems were the most common symptoms of exacerbation during pregnancy in women with MS. However, the results showed that 28% of people in the first trimester, 55% in the second trimester and 16.3% in the third trimester experienced few symptoms of MS. The results of this study, like other studies, showed that the symptoms of the disease in pregnancy would improve compared to prenatal and postpartum. This study showed that in the second trimester, there was a maximum recovery for the population under study too. Other studies showed in third trimester, the highest reduction in recurrence and return of MS symptoms compared to before prenatal period (10, 12). Another study showed that pregnancy had a protective role against MS and reduced 80% of recurrence, especially in the third trimester of pregnancy, which seems to increase the level of hormone, especially in the third trimester of pregnancy creates this protection (14). Perhaps it can be stated that the difference in the results of this study with other existing studies and documentation can be attributed to a smaller number of sample cases. The improvement of the condition of MS in the second trimester of pregnancy may also be attributed to adherence of the pattern of the disease to other chronic diseases, such as cardiovascular and inflammatory diseases get better condition during the second trimester.
In a study, it was indicated that although pregnancy for women with MS leads to a reduction in symptoms, a long-term 10-year examination showed that pregnant women do not differ with non-pregnant women in terms of long-term outcomes, and therefore it seems the probability that the pregnancy increases the risk of secondary attacks is very low (10). In the present study, it was also showed that patients had fewer symptoms during pregnancy.